{"title":"癌症纳米药物传递的药代动力学和毒性挑战","authors":"R. Dixit","doi":"10.35248/2329-6631.20.09.200","DOIUrl":null,"url":null,"abstract":"Nanomedicines are increasingly being used to diagnose, prevent and treat human diseases. Nanotechno- logical advances are enabling targeted delivery of difficult to deliver innovative therapies, including gene editing and disease correcting gene delivery, highly lipophilic cytotoxic cancer drugs, mod RNA, etc. Although nanomedicines offer great opportunities for targeted delivery, they have increasingly faced safety, disposi- tion, CMC and manufacturing challenges that have limited their utility.","PeriodicalId":15589,"journal":{"name":"Journal of Developing Drugs","volume":"103 1","pages":"5-5"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacokinetics and toxicity challenges to delivery of cancer nanomedicines\",\"authors\":\"R. Dixit\",\"doi\":\"10.35248/2329-6631.20.09.200\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Nanomedicines are increasingly being used to diagnose, prevent and treat human diseases. Nanotechno- logical advances are enabling targeted delivery of difficult to deliver innovative therapies, including gene editing and disease correcting gene delivery, highly lipophilic cytotoxic cancer drugs, mod RNA, etc. Although nanomedicines offer great opportunities for targeted delivery, they have increasingly faced safety, disposi- tion, CMC and manufacturing challenges that have limited their utility.\",\"PeriodicalId\":15589,\"journal\":{\"name\":\"Journal of Developing Drugs\",\"volume\":\"103 1\",\"pages\":\"5-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Developing Drugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2329-6631.20.09.200\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Developing Drugs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2329-6631.20.09.200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pharmacokinetics and toxicity challenges to delivery of cancer nanomedicines
Nanomedicines are increasingly being used to diagnose, prevent and treat human diseases. Nanotechno- logical advances are enabling targeted delivery of difficult to deliver innovative therapies, including gene editing and disease correcting gene delivery, highly lipophilic cytotoxic cancer drugs, mod RNA, etc. Although nanomedicines offer great opportunities for targeted delivery, they have increasingly faced safety, disposi- tion, CMC and manufacturing challenges that have limited their utility.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
